Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa
The U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based […]
Bausch + Lomb and Novaliq Announce FDA Approval of MIEBO™ for the Treatment of the Signs and Symptoms of Dry Eye Disease
Bausch + Lomb, a leading global eye health company dedicated to helping people see better […]
Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors
Prothena, a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on […]
Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas
Phio Pharmaceuticals, a clinical-stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to […]
Sarepta Therapeutics Announces Positive Vote from FDA Advisory Committee Meeting for SRP-9001 Gene Therapy to Treat Duchenne Muscular Dystrophy
Sarepta Therapeutics, the leader in precision genetic medicine for rare diseases, today announced that the […]
Otsuka and Lundbeck Announce FDA Approval of Supplemental New Drug Application for REXULTI® (brexpiprazole) for the Treatment of Agitation Associated with Dementia Due to Alzheimer’s Disease
Otsuka Pharmaceutical and Lundbeck announce the U.S. Food and Drug Administration (FDA) has approved the supplemental New […]
FDA Accepts Application for Roche’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
Roche has announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s […]
Brenus Pharma Unveils Groundbreaking Preclinical Results For STC-10101, a Promising New Drug Candidate Targeting Colorectal Cancer & Solid Tumors
Brenus Pharma announces two groundbreaking presentations on STC-1010, the company’s first drug candidate for colorectal […]
Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease
Editas Medicine, a clinical stage genome editing company, today announced that the US Food and […]
Vertex Announces FDA Approval for TRIKAFTA in Children With Cystic Fibrosis
Vertex Pharmaceuticals has announced the U.S. Food and Drug Administration (FDA) approved the expanded use […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more